Under the Panerwork Reduction Act of 1995 TRANSMITTAL FORM (to be used for all correspondence after initial Total Number of Pages in This Submission	And Unit	PTO/SB/21 (03-03) Approved for use through 04/30/2003. OMB 0651-0031 and Trademark Office; U.S. DEPARTMENT OF COMMERCE of information unless it displays a valid OMB control number. 09/464,426 12/16/1999 CARLOS O. STALGIS 1648 SHANON A. FOLEY IN0964O
	ENCLOSURES (Check all that	apply)
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Addre Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group 3 (Appeal Notice, Brief, Reply Brief) Proprietary Information 7 1 100 100 100 100 100 100 100 100 100
	TURE OF APPLICANT, ATTORNE	Y, OR AGENT
Firm SCHERING-PLOUGH COF PATENT DEPARTMENT, THOMAS D. HOFFMAN Signature Date DECEMBER 8, 2003		12/08/20N3
	EDTIFICATE OF TRANSMISSION	MAN INC
C	ERTIFICATE OF TRANSMISSION	/MAILING

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Date

Typed or printed

Signature

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/92 (08-03) (Modified)

Filing Date: 12/16/1999

Applicant: CARLOS O. STALGIS

Title: RIBAVIRIN-PEGYLATED INTERFERON ALFA INDUCTION HCV COMBINATION THERAPY

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 RECEIVED

DEC 1 6 2003

TECH OF THE

12/08/203

DEC. 8, 2003

Date

THOMAS D. HOFFMAN

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Documents enclosed:

AMENDMENT (7 pages)

RESPONSE TRANSMITTAL SHEET (1 page)

EXTENSION OF TIME (1 Month) (1 page in duplicate)

SEQUENCE LISTING STATEMENT (1 page)

COMPUTER READABLE DISK

RETURN POST CARD

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Patent Case No. IN0964Q

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Carlos O. Stalgis et al.

Examiner: Shanon A. Foley

For: RIBAVIRIN-PEGYLATED INTERFERON ALFA INDUCTION HCV COMBINATION THERAPY

Serial No.: 09/464,426

Filed: 12/16/99

Group Art Unit: 1648

COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria VA 22313-1450

Sir:



AMENDMENT

This is in response to the ex parte Quayle letter, dated 09/09/2003, stating that the application is in condition for allowance except for formal matters.

Applicants are amending this application to add the sequence listing and are enclosing herewith the following:

- (1) An initial computer readable form ("CRF") of the sequence listing;
- (2) A paper copy of the sequence listing;
- (3) A SEQUENCE LISTING STATEMENT;
- (4) A Petition and Fee for a One Month Extension of Time to Respond,
- (5) A Certificate of Mailing;
- (6) A return postcard; and
- (7) A Transmittal Letter.